Emerging retatrutide, a combined-action medication targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the medical community. Early clinical studies have demonstrated impressive decreases in physical size and improvements in physiological markers for people with excess weight . Scientists believe this novel